DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants

Phase 1

Withdrawn

Conditions: Healthy Participants

Interventions: Drug: BMS-986235 (Treatment A)
Drug: Rifampin (Treatment B)

First Posted Date: 2020-03-10

Last Posted Date: 2022-03-31

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT04301310

Locations: 🇺🇸
Local Institution, Salt Lake City, Utah, United States

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986256
Drug: Milk of magnesia

First Posted Date: 2020-02-13

Last Posted Date: 2022-01-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT04269356

Locations: 🇺🇸
Covance - Clinical Pharmacology Services - Madison, Madison, Wisconsin, United States

Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

Phase 2

Terminated

Conditions: Nonalcoholic Steatohepatitis (NASH)

Interventions: Drug: BMS-986263
Other: Placebo

First Posted Date: 2020-02-12

Last Posted Date: 2024-02-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 124

Registration Number: NCT04267393

Locations: 🇺🇸
Local Institution - 0150, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0171, Dallas, Texas, United States
🇺🇸
Local Institution - 0143, Redwood City, California, United States

and more 99 locations

A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Atazanavir/Cobicistat
Drug: Reyataz Atazanavir
Drug: Cobicistat

First Posted Date: 2020-02-10

Last Posted Date: 2021-11-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 34

Registration Number: NCT04263350

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165 prototype 2
Drug: BMS-986165 prototype 1
Drug: BMS-986165

First Posted Date: 2020-01-30

Last Posted Date: 2020-04-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 18

Registration Number: NCT04249284

Locations: 🇺🇸
Quotient Sciences Miami, Miami, Florida, United States

A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function

Phase 1

Completed

Conditions: Renal Failure

Interventions: Drug: BMS-986259

First Posted Date: 2020-01-23

Last Posted Date: 2021-09-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 30

Registration Number: NCT04237831

Locations: 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Prism Clinical Research, Saint Paul, Minnesota, United States

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: BMS-986263

First Posted Date: 2020-01-13

Last Posted Date: 2021-11-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT04225936

Locations: 🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States

A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165
Drug: Famotidine

First Posted Date: 2019-12-24

Last Posted Date: 2020-04-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 18

Registration Number: NCT04209699

Locations: 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Phase 3

Completed

Conditions: Bladder Tumor
Muscle-Invasive Bladder Cancer
Bladder Cancer

Interventions: Biological: Nivolumab
Procedure: Radical cystectomy (RC)
Biological: Bempegaldesleukin

First Posted Date: 2019-12-23

Last Posted Date: 2024-06-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 114

Registration Number: NCT04209114

Locations: 🇩🇪
Local Institution - 0117, Duesseldorf, Germany
🇨🇦
Local Institution - 0036, Sherbrooke, Quebec, Canada
🇨🇦
Local Institution - 0082, Oshawa, Ontario, Canada

and more 103 locations

A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Ipilimumab

First Posted Date: 2019-12-12

Last Posted Date: 2019-12-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 10

Registration Number: NCT04196452

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy